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Purpose: To develop an oral capsule-based chronomodulated drug delivery system of salbutamol 
sulphate for the treatment of nocturnal asthma. 
Methods: The basic design of the proposed dosage form entails an insoluble cross-linked capsule body 
filled with drug-loaded pellets sealed with hydrocolloid plug and a soluble capsule cap. Various 
hydrocolloid polymers, namely, hydroxypropyl methylcellulose, (HPMC), hydroxypropyl cellulose (HPC), 
sodium alginate, polyethylene oxide (PEO) and guar gum. were used to optimize the plug material in the 
delivery in order to modulate lag period To avoid gastric transit time variability, the entire system was 
coated with Eudragit S100/Eudragit L100 dispersion (4:1), an enteric polymer system that dissolves at 
pH 6.8.  
Results: Time-specific pulsatile release with 4 h lag period was achieved with crosslinked insoluble 
gelatin capsule shells containing pellets prepared from Avicel PH 101/lactose (80: 10) and 3 % Acidisol 
as disintegrant. In vitro data indicate that the developed pulsatile system released almost 98 % of the 
drug shoertly after the predetermined lag time of 4 h.   
Conclusion: The developed system is capable of releasing the drug after a 4-h lag period. However, in 
vivo studies need to be carried out to ascertain the effectiveness of the formulation. 
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INTRODUCTION 
 
In the last two decades, studies on 
chronopharmacokinetic and chronopharma-
codynamic parameters of various drugs gave 
convincingly evidence that paradigm of older 
“Homeostasis theory (constancy of milieu 
interne)” cannot be sustained any longer [1]. 
It is now well documented that most of the 
physiological functions of an organism 
display a natural synchronization with an 
internal 24-h rhythmic clock (circadian 
rhythm) which is controlled by sleep wake 
cycle. Few of the physiological processlikes 
such as lung function, heart rate, body 
temperature, liver function, blood flow and 
hormonal release, exhibit a peak time of 
functionality that is in accordance with these 
rhythmic cycles [2]. Diseases associated with 
the above physiological functions, including 
bronchial asthma, hypertension, myocardial 
infarction, angina pectoris, rheumatic 
disorders and ulcers, exhibit peak time of 
activity of function within a circadian rhythm 
[3].  
 
Asthma is one of the most common ailments 
with the largest circadian variation [4]. It is a 
disease of lung airways (bronchi) 
characterized by hyper-responsiveness to a 
variety of stimuli  [5,6].  Nocturnal asthma is 
defined as a variable nighttime exacerbation 
of the underlying asthma condition 
associated with increased airway 
responsiveness and worsening of lung 
functions [7]. The lung function (peak 
expiratory flow rate, FEV1) is usually highest 
at 4 pm and lowest at 4 am. Generally, 
asthma attacks are more prevalent in early 
morning [8]. It is inconvenient for a patient to 
take medicine at midnight. In this condition, a 
drug delivery system that can release the 
drug at a predetermined time to guarantee 
therapeutic efficacy is a prerequisite. This 
can be achieved by developing a pulsed 
release system capable of delivering the drug 
at the required time after a well-defined lag 
time [9-12].  
 
Multi-particulate systems are a better way of 
obtaining well-controlled regulation of drug 
release from oral dosage forms due to 
reduced risk of dose-dumping and 
reproducibility in release profile than the 
single unit systems [13-15]. 
 
The objective of this study was to develop a 
capsule system based on chronopharma-
ceutical approach for the treatment of 
nocturnal asthma using salbutamol sulphate 
as a model drug. The aim was to have a lag 
time of 4 h, i.e., the system is to be taken at 
bed time (10 pm) and is expected to release 
the drug after a period of 4 h, i.e., at 2 am. 
Literature evidence shows that the peak 
plasma concentration of salbutamol sulphate 
is reached approximately 2 h after oral 
administration. Therefore, the drug 
concentration would be at its maximum level, 
when asthma attacks are more prevalent, i.e., 






Salbutamol sulphate (Ranbaxy Research 
Laboratories, Gurgaon, India), microcry-
stalline cellulose (Avicel PH101 and PH 102, 
Jubiliant Organosys, New Delhi India), 
Eudragit L 100 and S 100 (Rohm Pharma, 
GmbH Germany) sodium alginate (SA), 
Hydroxypropyl methylcellulose (HPMC), 
hydroxypropyl cellulose (HPC),  polyethylene 
oxide (PEO), ethylcellulose (EC) (Ranbaxy 
Research Laboratories, Gurgaon, India) were 
obtained as gifts from the suppliers. Lactose 
and dicalcium phosphate (DCP) were 
purchased from DKSH, India. All other 
chemicals used were of analytical grade and 
obtained from authentic suppliers. 
 
Development of cross-linked gelatin 
capsule body 
 
In order to prepare insoluble gelatin capsule 
body, commercial empty gelatin capsule 
shells were exposed to formalin vapors 
generated by a reaction of 15 %v/v 
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formaldehyde solution with potassium 
permanganate. The caps of the capsules 
were not subjected to this treatment leaving 
them water soluble. The treatment was 
allowed to continue for 12 h followed by 
drying at 45 °C for 1 h and then at ambient 
temperature to remove residual 
formaldehyde. The cross-linked capsules 
shells were checked manually for any visual 
defects such as dimension, shape, pinholes 
etc. Solubility studies for cross-linked capsule 
shell were carried out in water, 0.1M HCl and 
phosphate buffer. A beaker containing 100 ml 
of the medium and cross-linked capsule 
shells was placed in a shaker system and 
shaken for 24 h. The capsules were capped 
with water-soluble caps and stored in air-tight 
containers until used [16]. 
 
Limit test for free formaldehyde 
 
The method reported by Mastiholimath et al 
[17] was used for this test. The reference 
solution used was 0.002 w/v formaldehyde 
solution. The test solution was prepared by 
soaking 25 formaldehyde treated capsule 
bodies in distilled water and stirred for 1 h 
with a magnetic stirrer to dissolve the free 
formaldehyde. The resulting solution was 
filtered, washed with distilled water and 
diluted to ten times with the washings. One 
milliliter of this test solution was taken into a 
test tube, mixed with 5 ml of acetone reagent 
and the volume adjusted to 10 ml with 
distilled water. The mixture was warmed at 
40 °C for 30 min over a water bath. The color 
intensity of the test solution was compared 
with that of the reference solution prepared in 
a similar manner using standard 
formaldehyde solution. To pass the test, the 
color intensity of the test solution should not 
be greater than that of the standard solution. 
 
Preparation of rapidly disintegrating 
pellets  
 
Rapidly disintegrating pellets were prepared 
by extrusion-spheronization method based on 
the composition in Table 1. Various 
combinations of microcrystalline cellulose 
(MCC), dicalcium phosphate (DCP) and 
lactose were studied as diluents for the 
preparation of the pellets  In order to achieve 
rapid release of the drug from the pellets, 3 % 
AcDiSol (croscarmellose sodium) was added 
as a super-disintegrant to the formulation. All 
the ingredients were sieved through 425 m 
screen and blended in a double-cone blender 
(Bhagwati Pharma machinery, India). Two 
percent PVP K-30 aqueous solution, as 
binding agent, was added and the mixture 
kneaded manually . The wet mass obtained 
was extruded through a 1.2 mm screen. The 
extrudate was spheronized for 3 min in 
spheronizer (Caleva MBS, UK)operating at 
800 - 1100 rpm. The pellets obtained were 
dried at 50 °C for 24 h in an oven and then 
sized through 1180 and 850 m sieve, 
respectively.  
 
Evaluation of pellets 
 
The pellets were evaluated for various 
physical parameters such as particle size 
distribution, bulk density, friability, flow 
properties and content uniformity as per 
standard procedure. Particle size was 
determined by sieve shaker method using 
sieves of different mesh sizes. Flow 
properties and content uniformity were 
evaluated as per the methods described in 
United State Pharmacopoeia 24 Shape and 
surface characteristics of the pellets were 
determined by scanning electron microscopy 
using gold sputter technique. The particles 
were vacuum-dried, coated with gold 
palladium and observed microscopically. 
 
Optimization of plug 
 
The formaldehyde-treated insoluble capsule 
bodies were separated from the soluble caps. 
A quantity of the pellets, equivalent to 100 mg 
of salbutamol sulphate, were weighed and 
filled into the insoluble capsule bodies 
manually, which were then plugged with 
baying quantities (10, 20 and 30 mg) of 
various hydrophilic polymers (HPMC, HPC, 
PEO and sodium alginate) to provide a lag 
time of  2 h. The polymer, in each case, was 
Qureshi et al  
 
Trop J Pharm Res, October 2012;11 (5): 706 
first compressed into a tablet in a hydraulic 
press (IR press, SV Scientific, Bangalore, 
India) and used as a plug. After insertion of 
plug, the cap and body of the capsule were 
sealed with 5 % ethyl cellulose ethanol 
solution.  
 
Enteric coating of capsules 
 
The sealed capsules were dip-coated with 10 
% w/w Eudragit L 100: S 100 dispersion in 
isopropyl alcohol containing 10 % triethyl 
citrate and 5 % talc as plasticizer and anti-
tack agent, respectively. Different 
concentration of Eudragit S100, L100 and 
their various combinations (1:1, 2:1 and 4:1) 
were studied. The capsules were removed 
from the dispersion when the coat build-up 
level reached 4, 6  and 8 %w/w and observed 
for coat uniformity, pores and cracks under 
microscope.. Coating level was determined 
as % weight gain of the capsule. The 
capsules were dried initially at room 
temperature for 30 min and then in a hot air 
oven at 40 °C for 24 h. After drying the 
capsules, they were subjected to 
disintegration test in 0.1M HCl for 2 h to 
determine the ability of the coat to withstand 
acid environment. Thereafter, the capsules 
were again subjected to microscopic 
examination to check for the integrity of the 
coat. The enteric coated capsules which 
passed the disintegration test were further 
evaluated for coating integrity in pH 5.5 since 
dissolution of coating in pH lower than 6.8 
may alter the required lag time. On the basis 
of solubility in pH 5.5 buffer, coating 
compositions and levels that fell short were 
rejected to avoid alteration of lag time. Only 
coating levels and compositions which were 
not dissolved at all or dissolved very slowly in 
pH 5.5 buffer were selected for further 
optimization of the most suitable enteric 
coating layer for pulsatile capsule. 
 
In vitro release studies 
 
The in vitro dissolution profiles of the 
developed system was studied using USP 2 
apparatus. The capsules were tied to the 
paddles with a cotton thread so that they 
remain immersed in the dissolution media. 
Dissolution was carried out in 0.1M HCl for 
initial  period of 2 h and then in phosphate 
buffer pH 6 and in simulating intestinal fluid 
for a further 4 h . The volume of the 
dissolution medium was 900 ml with the 
rotation speed set at 50 rpm and temperature 
at 37 ± 0.5 °C.  Samples (15 ml) were pipette 
out from dissolution flask at predetermined 
intervals, filtered using 0.45 m membrane 
filter and analyzed spectrophotometrically 
(UV-VIS, Shimadzu, Japan) at 274 nm. 
Simultaneously, withdrawn samples were 
also replaced with fresh buffer to maintain the 
sink condition throughout the dissolution 
study. 
 
Based on the results obtained for in vitro 
release profile and the lag time shown by the 
different formulations, the one which 
produced a desired release behavior and 
definite lag time of 4 h would be chosen as 
optimized formulation and subjected to 
stability studies and  in vivo studies 
 
Stability studies  
 
Stability studies were carried out to determine 
the effect of polymer or formulation additives 
on strength of drug as well and the physical 
stability of the formulation under accelerated 
storage conditions The optimized formulation 
was subjected to stability studies as per the 
ICH guidelines at 40 °C ± 5 °C and 75 % ± 5 
% RH. Samples were withdrawn at days 30, 
60 and 90 and analyzed for drug content and 
dissolution by HPLC [17]. The amount of drug 
remaining in the formulation after the stated 
period of time was determined by calculating 
degradation constant. Dissolution studies 
were also carried out to determine the 




For optimization studies on the plug material 
and coating level, ANOVA was performed. 
Differences were considered statistically 
significant at p < 0.05. The results are 
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Cross-inking of hard gelatin capsule 
 
Hard gelatin capsules bodies were cross-
linked with formaldehyde to make them 
insoluble. Solubility studies indicate that both 
untreated capsule bodies and caps dissolved 
within 20 min. while formalin-treated capsules 
bodies remained intact after 24 h.  
 
Limit test carried out to determine the 
presence of free formaldehyde in the treated 
capsules show that the color intensity of the 
test solution was less than that of standard 
formaldehyde solution indicating that free 
formaldehyde present in the treated capsule 
was within permissible limit (20µg free 
formaldehyde per 25 capsules). 
 
Physicochemical properties of pellets 
 
The pellets were prepared by extrusion-
spheronization technique. At a low 
spheronization speed (800 rpm), irregular 
pellets were formed while at a higher speed 
(1100 rpm or higher), mixed distribution of 
pellets shapes including rods, spheres, 
dumbbell and agglomerates were observed. 
Extrudate spheronized at 1000 rpm for 3 min 
produced more spherical spheres. On the 
basis of surface morphology and shape of the 
pellets, the best 5 formulations were selected 




The results of the optimization studies on the 
5 selected pellet formulations, in terms of flow 
properties and particle size distribution, are 
shown in Tables 2 and 3, respectively. 
 
On the basis of the data, formulation F4 was 
selected for the preparation of 
chronotherapeutic drug delivery system. 
Scanning electron microscopy revealed that 
F4 pellets had a smooth surface and a 
spherical shape (Figure 1) with a narrow 
particle size distribution. 
 
The yield, flow rate and mean particle size of 
formulation F4 was 74.7 %, 21.6 g/sec and 
890 µm, respectively while drug content was  
 
Table 1:  Composition and characteristics of five selected pellets formulations on the basis of good pellet 
appearance 
 
Ingredient (mg)  














F 1 5 70 - 20 - - 2 3 60 1000 3 Sp, SS, Gf 73.5 ± 11.2 
F2 5 - - - 30 60 2 3 60 1000 3 Sp, SS 79.0 ± 7.0 
F 3 5 - - - 70 20 2 3 60 1000 3 Sp, SS 76.8 ± 7.1 
F 4 5 - 80 10 - - 2 3 60 1000 3 Sp 74.7 ± 4.8 
F 5 5 - 70 20 - - 2 3 60 1000 3 Spl 66.8 ± 7.3 
Key: Av1 = Avicel PH101; Av2 = Avicel PH102; Lact = lactose; MCC = microcrystalline cellulose; DCP = dicalcium 
phosphate, PVP = polyvinyl pyrrolidone; Ac – AcDiSol, SP = spherical, SS = smooth surface. GF = good 
 
Table 2: Flow properties of selected pellets 
 




density  (g/cm3) 








F 1 23.43 0.625 0.731 1.16 14.50 0.73 
F 2 38.66 0.514 0.688 1.28 25.29 0.82 
F 3 28.72 0.689 0.886 1.28 22.23 0.53 
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Table 3: Particle size distribution selected formulations 
 
% Retained on mesh sieve 
Code 1180 µm 1000 µm 850 µm 710 µm Pan 
Mean particle size 
(µm) 











F 2 4.60 26.25 53.57 15.53 0.05 915 
F 3 7.40 21.54 68.57 2.45 0.05 886 
F 4 4.43 13.77 73.86 7.66 0.28 890 
F 5 4.93 16.77 69.86 8.16 0.28 898 
       
 
      
 
Figure 1:  Scanning electron micrograph of 




Figure 2: In vitro release profile of optimized pellet 
formulation (F4) in simulated intestinal fluid (pH 
6.8) 
 
96.6 %. Fig 2 shows rapid drug release from 
this formulation in pH 6.8 phosphate buffer, 
with approximately 90 % released in 35 min.   
 
Optimization of plug material 
 
The plug was aimed to delay the release for 2 
h after the dissolution of enteric layer in the 
intestinal environment. On the basis of 
amount of drug released at the end of 2h, 
plug ejection time (Table 4) as well as time 
taken to release 80 % of drug from the 
system (Table 5), a suitable plug material 
capable of preventing drug release for the 
proposed period was selected from among 
those in Tables 4 and 5.  
 
Table 4: Plug ejection time of various plug 
materials 
 
Plug ejection time (h) Plug 
material 10 mg 20 mg 30 mg 
HPC 1.5±0.5 3.0±0.4 3.0±0.4 
HPMC 1.0±0.5 3.0±0.3 4.5±0.4 
Na alginate 0.8±0.3 2.0± 0.3 3.5±0.5 
PEO 1.5±0.3 3.0±0.4 5.0±0.3 
Guar gum 0.5±0.5 1.5±0.29 2.5±0.3 
 
Table 5: Time taken to release approximately 




10 mg  20 mg  30  mg  
HPC 75 90 95 
HPMC 50 90 180 
Na alginate 45 120 180 
PEO 75 150 195 
Guar gum 30 75 75 
 
The results indicate that the best release 
profile was obtained with 20 mg sodium 
alginate as plug (Figure 3).  
 
Here again, the drug began to leach from the 
matrix prior to actual ejection but in a 
controlled pattern (initially slow but later on 
rapidly). In order to avoid leaching of drug 
before actual ejection of the plug, sodium 
alginate was blended with ethyl cellulose as a 
release modifier. The results obtained, shown 
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in Fig 4, indicate lag times of 1.5 (3:1), 2.0 
(1:1) and 3.5 h (1:3). Formulation containing 
sodium alginate/ethyl cellulose blend in 1: 1 
ratio as plug material showed a definite lag 
time of 2 h and a reduced early release of 
drug prior to actual ejection of plug. A 
complete burst effect was observed after a 
well-defined lag period. Consequently, it was 




Figure 3: In vitro release profile of capsule 
plugged with different amounts of sodium alginate 
() = 10 mg, ( ) = 20 mg () = 30 mg, of sodium 
alginate  
 
After insertion of plug, capsules were fitted 
with soluble caps and the joint was sealed 
with 5 % ethyl cellulose solution. Ethyl 
cellulose, due to its hydrophobic nature 
prevents entry of coating solution into the 
capsule during the coating process and 
prevents early drug release from the capsule. 
A significant difference was observed 
between all the formulation plugged with 
ethylcellulose/sodium alginate combination. 
 
Enteric coating of capsule 
 
Eudragit S 100 and L 100 singly or as blends 
of different ratios (1:1, 2:1 and 4:1) were used 
to coat the optimized capsule in order to 
determine the most suitable coating level. On 
the basis of disintegration and dissolution 
data, the most suitable combination of 
polymeric coating system and concentration 
was chosen. No pores and cracks were 
observed on coated capsule when subjected 
to microscopical examination. 
 
In order to ensure the desired lag time of the 
developed capsule system was maintained, 
enteric coating layer was assumed to be 
dissolved only in the region of pH 6.8. 
Solubilization of enteric coating at pH below 
than 6.8 would have altered the desired lag 
time which eventually may lead to the failure 
of system in terms of drug release at 
appropriate time. Therefore, to determine the 
specificity of the coating layer, enteric coated 
capsule were subjected to solubility test in pH 
5.5 and the coating layer which got dissolved 




Figure 4:   In vitro release profile of pulsatile 
capsule plugged with different amount of ethyl 
cellulose (EC) and sodium alginate (SA) mixture; 
= 15mg SA and 5 mg EC,   = 10 mg SA and 10 
mg EC, o = 5 mg SA and 15 mg EC 
 
The capsule coated with 6 % w/w Eudragit 
L100: S100 (1:4) or higher, did not dissolved 
in pH 5.5 buffer, hence 6 % w/w level was 
taken as the most suitable of all the 
formulations (Table 6). The coating slowly 
dissolved in pH 5.5 and took > 2 h to get 
dissolved, by which time, the capsule would 
already be in  
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S100: L100    
(4:1) 
Coating level (%w/w) 4 6 8 4 6 8 4 6 8 4 6 8 4 6 8 
Disintegration test   F P P F   F P P F P P P P P 
Solubility in pH 5.5 -- S NS -- S S - S S - S S S NS NS 
Mean lag time at pH 
6.8  (h) -- 1.3 2.8 -- 1.3 1.3 -- 1.3 1.8 - 1.3  1.9 2.0 2.3 
Key: F = Failed, coating layer broken down or dissolved within 2 h in 0.1 M HCl, P = Passed coating layer was intact 
even after 2 h in 0.1 M HCl, S= Soluble, NS = Not soluble  
 
the lower segment of the intestine where the 
pH is around 6.8, and hence lag time would 
not be affected.  
 
A significant difference (p < 0.05) was 
observed for capsule coated with 4% and 6 
% w/w of eudragit L100:S100 in a ratio of 1:4. 
But, there was no significant difference 
between the capsule coated with 6 and 8 % 
w/w. Fig 5 shows the dissolution profile of the 
pellets incorporated in this coated capsule in 
pH 1.2 and 6.8 media. Approx.97.7 % of the 
drug was released in pH 6.8 within a period 
of 2.25 h. 
 
Figure 5: Dissolution profile of the final optimized 
capsule formulation in 0.1M HCl (for the first 2 h) 




Drug content in the optimized formulation 
degraded by 3.26 % (less than 5 %) in a 
period of three months suggesting that the 
formulation is stable on storage. Degradation 
constant was 20.7 x 10-5. No alteration in lag 
time was observed based on dissolution 
studies carried out after the storage period, 




In order to modify the solubility of gelatin 
capsule bodies, Schiff’s base condensation 
was employed. When gelatin capsule bodies 
were exposed to formalin vapors, the amino 
group present in the gelatin molecular 
structure undergoes cross-linking with the 
aldehyde group present in formaldehyde 
molecule, as per Schiff’s base condensation, 
resulting in decreased aqueous solubility of 
gelatin [18]. 
 
Avicel PH101 in combination with lactose 
formed pellets with smooth surface 
characteristics. Increase in Avicel PH 101 
content might have increased the plasticity of 
the pellets; and therefore can be easily 
deformed toa spherical shape during 
spheronization. Previous studies found that a 
mixture of Avicel PH101 and lactose in a ratio 
of (80:10) along with AcDiSol as 
superdisintegrant produced good pellets in 
terms of shape, flow property and release 
profile [19 ,20]. The pellets exhibited rapid 
drug release due probably to the presence of 
AcDiSol which acts as superdisintegrant and 
would have facilitated bursting of the pellets. 
Various hydrocolloids were evaluated in this 
study for the optimization of plug material 
plug to provide a 2 h lag time. With most of 
the material studied, sustained drug release 
behavior was observed instead of rapid 
release. This characteristic may be attributed 
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to matrix formation, with the plug adhered to 
the capsule body even after the desired lag 
time. Nevertheless, better release profile was 
obtained with 20 mg sodium alginate as a 
plug than with other polymers. However, drug 
leaching began prior to ejection of the plug 
and hence ethyl cellulose, which is 
hydrophobic, was used and this had a 
retarding effect on drug release. The 
formulation containing sodium alginate and 
ethyl cellulose (1: 1) as plug material showed 
a definite lag time of 2 h and a reduced early 
release of drug before actual ejection of plug.  
The plug was completely detached from the 
capsule body after the desired lag time due to 
less stickiness and weak mechanical strength 
of the matrix formed with sodium 
alginate/ethyl cellulose blend [21]. 
 
The proposed system was designed to 
release drug after 4 h lag time when the 
dosage form would probably be in the middle 
part of the small intestine where it would  
remain for a maximum period. In order to 
avoid the variability of gastric emptying and to 
prevent the start of drug release in stomach, 
the capsule was coated with Eudragit S100/L 
100 since pH-sensitive Eudragit polymers are 
ionized and solubilized in a range of pH 
rather than at a definite pH. Since coating 
was aimed to dissolve at pH 6.8 (middle part 
of the intestine), dissolution of coating 
material and drug release below or above this 
pH will ultimately shift the lag time. On the 
basis of disintegration in 0.1M HCl, and 
dissolution in phosphate buffer pH 5.5 and 
pH 6.8, most appropriate polymer ratio and 
level was selected. The enteric coat of 
Eudragit S100/L 100 (4:1) remained intact for 
2 h in pH 1.2, but dissolved at intestinal pH of 
6.8. The soluble cap of the capsule had 
dissolved completely after 15-20 min and 
thus exposed the polymer plug which 
absorbed the surrounding fluid, swelled and 
released the drug through the swollen matrix. 
Following complete wetting of the plug, it 
might have formed a soft mass which was 
then easily ejected out of the capsule body, 
thus releasing the pellets into the medium 
which readily dissolved and complete drug 




Controlled pulsatile release of drug after a 
programmed 4 h lag period was achieved 
from cross-linked gelatin capsule shells 
containing salbutamol pellets, and sealed 
with a suitable mixture of sodium alginate and 
ethyl cellulose as plug. Thus, the developed 
capsule-based delivery system is a promising 
formulation for time-controlled delivery of 
salbutamol for the management of nocturnal 
asthma. However, in vivo studies are 





The authors are thankful to University Grants 
Commission of India for providing financial 




1. Lemmer B. Chronopharmacology and controlled 
drug release. Expert Opin. Drug Deliv. 2005; 
2(4): 667-681. 
2. Levi F, Schibler U. Circadian Rhythms: Mechanisms 
and Therapeutic Implications. Annual  Rev. 
Pharmacol.  Toxicol. 2007; 47: 593-628. 
3. Mandal AS, Biswas N, Karim KM, Guha A, 
Chatterjee S, Behera M, Kuotsu K. Drug  
delivery system based on chronobiology.  J. 
Control. Rel. 2010; 147: 314–325. 
4. Vianna EO. Mechanisms and Therapeutic 
Implications of Asthma Circadian Rhythm. 
Curr. Resp. Med. Rev. 2005; 13: 171-183. 
5. Guinee DG, Dail. Hammar’s Pulmonary Pathology: 
Nonneoplastic lung disease. New York:  
Springer: edn 3, 2008.  
6. Baroffio M,  Barisione G, Crimi E,  Brusasco V. 
Noninflammatory Mechanisms of Airway 
Hyper-responsiveness in Bronchial Asthma: 
An Overview. Ther. Adv. Resp. Disease. 2009; 
3(4): 163-174. 
7. Richard JM, Schlegel SB. Chronobiology of 
Asthma. Am. J. Respir. Crit. Care Med. 1998; 
158 (3): 1002-1007. 
8. Pincus DJ, Beam WR, Martin RJ Chronobiology 
and chronotherapy of asthma. Clin Chest Med 
1995; 16 (4): 699-713. 
9. Pincus DJ, Humeston TR, Martin RJ. Further 
studies on the chronotherapy of asthma with 
inhaled steroids: the effect of dosage timing on 
Qureshi et al  
 
Trop J Pharm Res, October 2012;11 (5): 712 
drug efficacy. J Allergy Clin. Immunol. 1997; 
100(6): 771-774. 
10. Richard JM, Susan BS Chronobiology of asthma. 
Am. J. Resp. Crit. Care Med. 1998; 158: 1002-
1007. 
11. Gwen SS. Nocturnal asthma: mechanism and 
management. Mount Sinai J Med. 2002; 69: 
140-147. 
12. Li B, Zhu JB, Zheng CL, Gong W. A novel system 
for three-pulse drug release based on “tablets 
in capsule” device. Int. J. Pharm. 2008; 352(1-
2): 159-164. 
13. Takada K, Yoshikawa H. In: E Mathiowitz (Ed), 
Encyclopedia of controlled drug delivery, 
Willey, New York, 1999. pp 728-742. 
14. Borgquist P, Nevsten P, Nilsson B, Wallenberg LR, 
Axelsson A.  Simulation of the release from a 
multiparticulate system validated by single 
pellet and dose release experiments.  2004; 97 
(3): 453-465. 
15. Morta R, Jose L, Vil J Design of new 
multiparticulate system for potential site 
specific and  controlled drug delivery to the 
colonic region. J. Control. Rel. 1998; 55: 67-
77. 
16. Mastiholimath VS, Dandagi PM, Jain SS, Gadad 
AP, Kulkarni AR. Time and pH dependent 
colon specific, pulsatile delivery of theophylline 
for nocturnal asthma. Int. J Pharm. 2007; 328: 
49-56. 
17. Sane RT, Gangal DP, Tendulkar RV, Kothurkar 
RM.,Ladage KD. HPLC method for 
determination of salbutamol sulphate. Ind. J. 
Pharma. Sci. 1990; 52: 197-199. 
18. Philip AK, Philip B. Phase transited and vapor-
induced dual capsular system (DCS) for 
achieving delayed and osmotic release of 
cefadroxil. Pharm. Dev. Tech. 2011; 16(5): 
457-465.  
19. Rudnic EM; Schwartz JB. Remington: The science 
and practice of pharmacy, Baltimore, USA: 
Lippincott Williams and Wilkins: edn 21, 2006; 
pp 889-917. 
20. Rehman MA, Ali J. Development and in vitro 
Evaluation of Enteric Coated 
MultiparticulateSystem for Resistant 
Tuberculosis. Ind. J. Pharm Sci. 2008; 70(4): 
477-481. 
21. Roy P, Shahiwala AA. Multiparticulate formulation 
approach to pulsatile drug delivery: Current 
perspectives. J. Control. Rel. 2009; 134: 74-
80. 
 
 
  
